Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer

Journal of Cell Communication and Signaling

Volumn 9, Issue 4, 2015, Pages 327-339

  Riser, Bruce L ^a,b   Barnes, Jeffrey L ^c   Varani, James ^d  

^a BLR Bio LLC   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biotherapeutics; Cancer and tumor stroma; CCN2 CTGF; Chronic kidney disease; Diabetic nephropathy; Extracellular matrix pathobiology; Mesangial cells; Nephrogenic systemic sclerosis; Podocytes; Skin scarring; Tissue homeostasis

Indexed keywords

BLR 101; BLR 102; CCN PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; PAMREVLUMAB; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; FIBROSING ALVEOLITIS; FIBROSIS; GENETIC TRANSCRIPTION; HUMAN; IN VIVO STUDY; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY FIBROSIS; LIVER FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RENAL PROLIFERATIVE DISEASE; SIGNAL TRANSDUCTION; SKIN FIBROSIS; TREATMENT INDICATION;

EID: 84954403561     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-015-0309-3     Document Type: Article

References (71)

1. Abd El Kader T, Kubota S, Janune D, et al. (2013) Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family. J Cell Commun Signal 7:11–18. doi:10.1007/s12079-012-0180-4
2. Abrahams AC, Habib SM, Dendooven A, et al. (2014) Patients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor-β1, and vascular endothelial growth factor. PLoS One 9:e112050. doi:10.1371/journal.pone.0112050
3. Adler SG, Kang SW, Feld S, et al. (2002) Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria? Am J Kidney Dis 40:184–188. doi:10.1053/ajkd.2002.33928
4. Aguiar DP, de Farias GC, de Sousa EB, et al. (2014) New strategy to control cell migration and metastasis regulated by CCN2/CTGF. Cancer Cell Int 14:61. doi:10.1186/1475-2867-14-61
5. Barnes JL, Gorin Y (2011) Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int 79:944–956. doi:10.1038/ki.2010.516
6. Bhagavathula N, Dame MK, DaSilva M, et al. (2010) Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Investig Radiol 45:769–777. doi:10.1097/RLI.0b013e3181e943d2
7. Bhagavathula N, DaSilva M, Aslam MN, et al. (2009) Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Investig Radiol 44:433–439. doi:10.1097/RLI.0b013e3181a4d7e9
8. Bleavins K, Perone P, Naik M, et al. (2012) Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 145:257–267. doi:10.1007/s12011-011-9176-9
9. Borkham-Kamphorst E, Huss S, Van de Leur E, et al. (2012a) Adenoviral CCN3/NOV gene transfer fails to mitigate liver fibrosis in an experimental bile duct ligation model because of hepatocyte apoptosis. Liver Int 32:1342–1353. doi:10.1111/j.1478-3231.2012.02837.x
10. Borkham-Kamphorst E, Van Roeyen CR, Van De Leur E, et al. (2012b) CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC. J Cell Commun Signal 6:11–25. doi:10.1007/s12079-011-0141-3
11. Bornstein P (2009) Matricellular proteins: an overview. J Cell Commun Signal 3:163–165
12. Bremnes RM, Dønnem T, Al-Saad S, et al. (2011) The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 6:209–217. doi:10.1097/JTO.0b013e3181f8a1bd
13. Brigstock DR (2003) The CCN family: a new stimulus package. J Endocrinol 178:169–175. doi:10.1677/joe.0.1780169
14. Cicha I, Yilmaz A, Klein M, et al. (2005) Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro. Arterioscler Thromb Vasc Biol 25:1008–1013. doi:10.1161/01.ATV.0000162173.27682.7b
15. Cokonis Georgakis C-D, Falasca G, Georgakis A, Heymann W (2006) Scleromyxedema. Clin Dermatol 24:493–497. doi:10.1016/j.clindermatol.2006.07.011
16. Cowper SE, Robin HS, Steinberg SM, et al. (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001
17. DaSilva M, O’Brien Deming M, Fligiel SEG, et al. (2010) Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Investig Radiol 45:733–739. doi:10.1097/RLI.0b013e3181e9436b
18. Do C, Barnes JL, Tan C, Wagner B (2014) Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Ren Physiol 307:F844–F855. doi:10.1152/ajprenal.00379.2014
19. Grobner T, Prischl FC (2007) Gadolinium and nephrogenic systemic fibrosis. Kidney Int 72:260–264. doi:10.1038/sj.ki.5002338
20. Guha M, Xu Z-G, Tung D, et al. (2007) Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21:3355–3368. doi:10.1096/fj.06-6713com
21. Gupta S, Clarkson MR, Duggan J, Brady HR (2000) Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58:1389–1399. doi:10.1046/j.1523-1755.2000.00301.x
22. Ha TS, Barnes JL, Stewart JL, et al. (1999) Regulation of renal laminin in mice with type II diabetes. J Am Soc Nephrol 10:1931–1939
23. Holbourn KP, Acharya KR, Perbal B (2008) The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33:461–473. doi:10.1016/j.tibs.2008.07.006
24. Hudkins KL, Pichaiwong W, Wietecha T, et al. (2010) BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 21:1533–1542. doi:10.1681/ASN.2009121290
25. Hutchenreuther J, Vincent KM, Carter DE, et al. (2015) CCN2 expression by tumor stroma is required for melanoma metastasis. J Investig Dermatol. doi:10.1038/jid.2015.279
26. Ito Y, Aten J, Bende RJ, et al. (1998) Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853–861. doi:10.1111/j.1523-1755.1998.00820.x
27. Ito Y, Goldschmeding R, Bende R, et al. (2001) Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol 12:472–484
28. Jun J-I, Lau LF (2011) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10:945–963
29. Khurana A, Runge VM, Narayanan M, et al (2007) Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).
30. Kovalenko E, Tacke F, Gressner OA, et al. (2009) Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat 16:612–620. doi:10.1111/j.1365-2893.2009.01110.x
31. Li G, Xie Q, Shi Y, et al. (2006) Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 8:889–900. doi:10.1002/jgm.894
32. McCallum L, Lu W, Price S, et al. (2009) CCN3: a key growth regulator in chronic myeloid leukaemia. J Cell Commun Signal 3:115–124. doi:10.1007/s12079-009-0058-2
33. McCallum L, Price S, Planque N, et al. (2006) A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 108:1716–1723. doi:10.1182/blood-2006-04-016113
34. McNeill AM, Barr RJ (2002) Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol 41:364–367. doi:10.1111/j.1365-4632.2002.1488_3.x
35. National Institutes of Health, National Institutes of Diabetes & Digestive & Kidney Disease D of KU& HD (2011) USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.
36. Nguyen TQT, Tarnow L, Andersen S, et al. (2006) Urinary connective tissue growth factor excretion correleates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 29:83–88
37. Oemar BS, Werner A, Garnier J-M, et al. (1997) Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 95:831–839
38. Ortonne N, Lipsker D, Chantrel F, et al. (2004) Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol 150:1050–1052. doi:10.1111/j.1365-2133.2004.05900.x
39. Paradis V, Dargere D, Vidaud M, et al. (1999) Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 30:968–976. doi:10.1002/hep.510300425
40. Parving H-H, Hovind P (2002) Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep 4:387–393. doi:10.1007/s11906-002-0069-3
41. Perbal B (2001) NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 54:57–79. doi:10.1136/mp.54.2.57
42. Perone PA, Weber SL, DaSilva M, et al. (2010) Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Investig Radiol 45:42–48. doi:10.1097/RLI.0b013e3181bf95eb
43. Quan TE, Cowper S, Wu SP, et al. (2004) Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 36:598–606
44. Riser BL, Bhagavathula N, Perone P, et al. (2012) Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis. J Cell Commun Signal 6:97–105. doi:10.1007/s12079-012-0164-4
45. Riser BL, Cortes P, DeNichilo M, et al. (2003) Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int 64:451–458. doi:10.1046/j.1523-1755.2003.00130.x
46. Riser BL, Cortes P, Yee J (2000a) Modelling the effects of vascular stress in mesangial cells. Curr Opin Nephrol Hypertens 9:43–47
47. Riser BL, Denichilo M, Cortes P, et al. (2000b) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25–38
48. Riser BL, Ladson-Wofford S, Sharba A, et al. (1999) TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int 56:428–439. doi:10.1046/j.1523-1755.1999.00600.x
49. Riser BL, Najmabadi F, Garchow K, et al. (2014) Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy. Am J Pathol 184:2908–2921. doi:10.1016/j.ajpath.2014.07.009
50. Riser BL, Najmabadi F, Perbal B, et al. (2009) CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 174:1725–1734. doi:10.2353/ajpath.2009.080241
51. Riser BL, Najmabadi F, Perbal B, et al. (2010) CCN3/CCN2 regulation and the fibrosis of diabetic renal disease. J Cell Commun Signal 4:39–50. doi:10.1007/s12079-010-0085-z
52. Ritz E, Rychlík I, Locatelli F, Halimi S (1999) End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 34:795–808. doi:10.1016/S0272-6386(99)70035-1
53. Roestenberg P, van Nieuwenhoven FA, Joles JA, et al. (2006) Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Ren Physiol 290:F1344–F1354. doi:10.1152/ajprenal.00174.2005
54. Rongioletti F, Cozzani E, Parodi A (2010) Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare. J Cutan Pathol 37:1084–1087. doi:10.1111/j.1600-0560.2009.01386.x
55. Segarini PR, Nesbitt JE, Li D, et al. (2001) The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem 276:40659–40667. doi:10.1074/jbc.M105180200
56. Shimoyama T, Hiraoka S, Takemoto M, et al. (2010) CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration. Arterioscler Thromb Vasc Biol 30:675–682. doi:10.1161/ATVBAHA.110.203356
57. Sieber MA, Lengsfeld P, Frenzel T, et al. (2008) Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 18:2164–2173. doi:10.1007/s00330-008-0977-y
58. Slagman MCJ, Nguyen TQ, Waanders F, et al. (2011) Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. Clin J Am Soc Nephrol 6:1845–1850. doi:10.2215/CJN.08190910
59. Soler MJ, Riera M, Batlle D (2012) New experimental models of diabetic nephropathy in mice models of type 2 diabetes: Efforts to replicate human nephropathy. Exp Diabetes Res 2012:
60. Swartz RD, Crofford LJ, Phan SH, et al. (2003) Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114:563–572. doi:10.1016/S0002-9343(03)00085-8
61. Tam FWK, Riser BL, Meeran K, et al. (2009) Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 47:37–42. doi:10.1016/j.cyto.2009.04.001
62. Tsoutsman T, Wang X, Garchow K, et al. (2013) CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure. J Mol Cell Cardiol 62:164–178. doi:10.1016/j.yjmcc.2013.05.019
63. van Roeyen CRC, Eitner F, Scholl T, et al. (2008) CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 73:86–94. doi:10.1038/sj.ki.5002584
64. Varani J, DaSilva M, Warner RL, et al. (2009) Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Investig Radiol 44:74–81. doi:10.1097/RLI.0b013e31818f76b5
65. Wagner B, Tan C, Barnes JL, et al. (2012) Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model. Am J Pathol 181:1941–1952. doi:10.1016/j.ajpath.2012.08.026
66. Wahab NA, Weston BS, Mason RM (2005) Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 16:340–351. doi:10.1681/ASN.2003100905
67. Wermuth PJ, Wermuth PJ, Del Galdo F, et al. (2009) Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 60:1508–1518. doi:10.1002/art.24471
68. Weston BS, Wahab NA, Mason RM (2003) CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. J Am Soc Nephrol 14:601–610. doi:10.1097/01.ASN.0000051600.53134.B9
69. Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117:524–529. doi:10.1172/JCI31487
70. Yokoi H, Mukoyama M, Mori K, et al. (2008) Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 73:446–455. doi:10.1038/sj.ki.5002722
71. Yokoi H, Mukoyama M, Nagae T, et al. (2004) Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 15:1430–1440. doi:10.1097/01.ASN.0000130565.69170.85